Xtalks Life Science Webinars
This strategy focuses on Phases I and II, aiming to achieve proof-of-concept as efficiently as possible, completing all learning required to plan a comprehensive and effective Phase III program.
TORONTO (PRWEB)
July 18, 2023
Bringing new hope to the field of small pharma, a webinar addressing a novel service paradigm for efficient Phase I and II trials is set to take place. The event will provide a fresh perspective on how small pharma, including emerging, virtual and small biotechnology companies, can navigate the complexities of early clinical development.
These organizations often find themselves navigating a fragmented vendor network and relying on multiple contract development and manufacturing organizations (CDMOs). This approach, however, often lacks the comprehensive expertise and strategic planning required to efficiently address the intricacies of early clinical development.
The upcoming webinar will introduce a new concept — intelligent drug development. This strategy focuses on Phases I and II, aiming to achieve proof-of-concept as efficiently as possible, completing all learning required to plan a comprehensive and effective Phase III program. The model allows small pharma access to a multi-disciplinary team that builds and drives a strategic plan, enhancing scientific knowledge and ensuring maximum flexibility, coordination and speed.
The strategic team will guide small pharma sponsors in building the strategic plan, selecting and coordinating partners from the fragmented vendor space and interpreting emerging clinical data to lay the foundations for the next stages of clinical and drug product development.
Leading the discussion for the PPD clinical research business of Thermo Fisher Scientific will be experts from the Strategic Development Consulting team, Gary M. Klaich, PhD, Senior Nonclinical Strategy Director, and Kevin M. Kane, PhD, CMC Strategy Director.
The PPD, clinical research business, is renowned for its commitment to accelerating innovation and increasing drug development productivity. The business covers multiple therapeutic areas and includes early development, all phases of clinical development, peri- and post-approval strategies and comprehensive laboratory services.
The collaboration between the PPD clinical research business and Xtalks for this event represents a shared commitment to providing valuable insights and guidance to small pharma organizations, helping them navigate the intricacies of early clinical development.
The live webinar will take place on Thursday, July 27, 2023, at 10 am EDT (4 pm CEST/EU-Central). Don’t miss this opportunity to learn about the new intelligent drug development paradigm, designed to support small pharma in efficiently navigating early clinical development.
For more information, or to register for this event, visit Intelligent Drug Development: A New Service Paradigm for Small Pharma.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: